ALEXANDRIA KOUKOS: Open Payments
NPI 1205608619 · HAMDEN, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,310 in 154 payments from 30 companies in 2025. Trend: 2023 $400 · 2024 $3,509 · 2025 $3,310
Food & beverage: $3,310
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 29 | $581 |
| AstraZeneca Pharmaceuticals LP | 12 | $251 |
| Lilly USA, LLC | 14 | $244 |
| Novo Nordisk Inc | 9 | $242 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $198 |
| Axsome Therapeutics, Inc. | 12 | $188 |
| Indivior Inc. | 7 | $185 |
| Vanda Pharmaceuticals Inc. | 8 | $178 |
| GlaxoSmithKline, LLC. | 9 | $163 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 9 | $159 |
Products named: VRAYLAR, CAPLYTA, SUBLOCADE, FANAPT, TRELEGY ELLIPTA, MOUNJARO, Wegovy, XIFAXAN.
Industry payments across CT — which companies pay providers there.
